meRfi®-GM
Esophageal adenocarcinoma (EAC)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Esophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's esophagus is the biggest risk factor.
The incidence of Esophageal Adenocarcinoma (EAC) / Esophageal cancer has increased in recent decades, and its 5-year survival rate is less than 20%. As a well-established precursor, patients with Barrett's esophagus (BE) have a persistent risk of progression to EAC. Many researchers have already identified some factors that may contribute to the development of BE and EAC, and the identified risks include [gastroesophageal reflux (GER)](brain://RAf2yfP3uEaEkcesXg_mIQ/Gastr…
References (Sources)
- DJ-1 promotes cell proliferation and tumor metastasis in esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway
- Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study
- Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial
- Nomograms to predict survival rates for esophageal cancer patients with malignant behaviors based on ICD-0-3
- Prognostic impact of tumor-associated macrophage infiltration in esophageal cancer: a metaanalysis
- Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
- The expression and prognostic value of SOX2, β-catenin and survivin in esophageal squamous cell carcinoma